The human antibody repertoire represents a largely untapped source of potential therapeutic antibodies and useful biomarkers. While current computational methods, such as next generation sequencing (NGS), yield enormous sets of data on the antibody repertoire at the sequence level, functional data is required to identify which sequences are relevant for a particular antigen or set of antigens. Here, we describe a method to identify and recover individual antigen-specific antibodies from peripheral blood mononuclear cells (PBMCs) from a human blood donor. This method utilizes an initial enrichment of mature B cells and requires a combination of phenotypic cell markers and fluorescently-labeled protein to isolate IgG memory B cells via flow cytometry. The heavy and light chain variable regions are then cloned and re-screened. Although limited to the memory B cell compartment, this method takes advantage of flow cytometry to interrogate millions of B cells and returns paired heavy and light chain sequences from a single cell in a format ready for expression and confirmation of specificity. Antibodies recovered with this method can be considered for therapeutic potential, but can also link specificity and function with bioinformatic approaches to assess the B cell repertoire within individuals.
Introduction
Antibodies are a growing class of therapeutic molecules, and the existing B cell repertoire in any human is a potential source of such antibodies. When recovered from a human donor, they require no adaptation or "humanization", steps that are required for antibodies generated in other animal systems. Several methods exist for the identification and isolation of human antibodies, including B cell activation and proliferation 1 , immortalization via EBV transformation 2, 3 , and generation of hybridoma cell lines 4, 5 . However, all of these methods require extensive cell culture to screen and recover antigen-specific antibodies. Information about the human antibody repertoire has been greatly expanded with the development of next generation sequencing (NGS) technology, allowing for the identification of massive amounts of individual sequences present in donor samples. However, because NGS yields an agnostic view of all sequences present, it does not allow for the identification and isolation of antigen-specific antibodies, especially in the case of rare or low frequency antibodies.
The purpose of the "BSelex" method is to identify antigen-specific antibodies from circulating peripheral blood mononuclear cells in human donors, and isolate and recover the sequences of these antibodies for further analysis. This method utilizes flow cytometry and cell sorting to take advantage of the B cell receptor (BCR) expressed on the surface of memory B cells. Millions of B cells can be screened for antigenspecificity via flow cytometry before the more low-throughput molecular biology methods are initiated. Paired heavy and light chain identification is not possible in most NGS methods, which analyze cell sequences in bulk. In the method we describe here, cells are isolated individually, and paired recovery of both heavy and light chain sequences is possible, which allows direct cloning and expression of the full IgG.
Protocol
The use of samples from human volunteers followed protocols approved by The Scripps Research Institute Institutional Review Board. Informed consent was obtained from the donors prior to the blood donation. 3. Use 2.5 µL of the Step I product as template for each (Step II) PCR reaction. Add the pool of forward primers specific to the HC and LC (κ and λ) framework 1 region and a pool of reverse primers specific to the junction region of each antibody chain. Double the 10x polymerase buffer to 2x concentration, and run PCR reactions 50 cycles each using the same parameters as Step I. 4. Run the completed PCR reactions on 1% agarose gel to visualize positive amplification hits. Recover paired amplicons (both heavy and light chain from the same cell) and isolate via gel extraction. Determine DNA fragment concentration via OD 260 for accurate ligation mix calculations. 5. Combine recovered heavy and light chain fragments with a linker fragment and the expression vector backbone using a 4-fragment ligation reaction using a commercial kit. 6. Transform ligation reactions into chemically competent bacteria using a commercial kit. Once plated onto antibiotic plates, add 4 mL of growth media (with antibiotic) to the remaining transformation culture, and incubate 37 °C overnight at 250 rpm. This is the "ligation mix culture." 7. Prepare miniprep DNA from the overnight ligation mix cultures using a commercial kit, and determine the resulting plasmid DNA concentration.
Single Cell Cloning

ELISA Screen for Confirmation of Antigen-specificity
1. Transfect 10 µg of miniprep DNA with cationic lipid-based reagent into 10 mL of suspension 293 cells, and incubate for 3-4 days at 37 °C (8% CO 2 ) while rotating at 125 rpm. For harvest, centrifuge culture 10 min at 1,000 x g and recover clarified media. 1. Measure the IgG concentration in the supernatants via affinity to Protein A. 2. Test each IgG (in supernatant) at 20 µg/mL by enzyme-linked adsorbent assay (ELISA) against the individual peptides used for the sort, captured on a streptavidin plate or actin as a negative control. Use a goat anti-human peroxidase secondary antibody against human IgG Fab to detect recombinant clones. After subtraction of background, OD > 0.5 is defined as screen positive. 3. Confirm screen positive hits by performing an additional ELISA, using dilutions of IgG supernatant to generate a concentration curve starting at 20 µg per mL, and plotting against OD for each antigen showing reactivity in the initial screen ELISA.
Representative Results
This method covers a multi-step process to isolate antigen-specific antibodies from human donors. In the representative data shown here, cells were incubated with a pool of fluorescently-labeled peptides representing several different domains of the tau protein, including phosphorylated peptides to mimic putative phosphorylation sites. These peptides were used as "bait" to identify cells that are reactive with tau epitopes(s) of interest. In preparation for sorting, a panel of fluorescently-labeled phenotypic markers were used to identify different cell populations within the enriched B cell population. A series of cytometry gates were devised to isolate the target memory B cells (Figure 1) . Lymphocytes were isolated based on their cell size and granularity using forward scatter (FSC) and side scatter (SSC) plots in flow cytometry 6, 7 . Following exclusion of multiple cells ("doublets") and dead cells, phenotypic markers allowed the segregation of IgG + memory B cells via IgG, CD19 (B cell) and CD27
(memory). In this approach, the CD27 marker does not distribute into two discrete populations, so the top 45% of CD27 amplicons is usually between 25-40% efficiency. These efficiencies vary between donor pools, and the representative data (Figure 3) is an example of very efficient amplification from 24 single cells (42% paired recovery). Following IgG cloning, the IgG expression vector is transfected into human embryonic kidney (HEK-293) suspension cells, which are used to maximize expression. The use of serum-free medium reduces contaminating proteins from the recombinant antibody prep, and helps minimize noise in subsequent binding assays. The recovered antibodies are screened against the original panel of tau peptides and scored for reactivity by ELISA (Figure 4 ). An initial threshold of OD = 0.5 above background is used to indicate positive antigen reactivity, and β-actin protein is used as a control for non-specific binding. If the flow cytometry and sorting steps use a mixed pool of peptides, the screening ELISA is the first step of deconvoluting specific reactivities of the recovered IgGs. Three of the 10 IgGs assayed demonstrated reactivity against phosphorylated CBTAU22.1 peptide, and one was reactive to non-phosphorylated CBTAU27.1 (Figure 4A) . Additional confirmation was completed using a concentration curve of the same recombinant antibody samples against the peptides identified in the initial screen, and an additional peptide as a negative control (Figure 4B) . For each positive hit, an individual plasmid clone was isolated from the transformed pool and reconfirmed by the same ELISA method. Only Clone 34 is shown the data presented, and while reactivity to non-phosphorylated CBTAU27.1 was confirmed, lower affinity binding was also observed with the phosphorylated 27.1 peptide (Figure 4C ). 
Discussion
The method presented here combines flow cytometry and single cell cloning, and the methods we describe here we based on methods previously developed by Tiller and colleagues 11 . Their work describes the recovery and cloning of monoclonal antibodies in order to study the B cell repertoire in humans at the level of individual cells. We have adapted the major components of their process to allow recovery of antigenspecific monoclonal antibodies from a population of memory B cells, including the multi-step amplification primer strategy. The major modification is the addition of labelled antigen "bait". Additional adaptations have been made to the published protocol, including (but not limited to) modifying the cloning vector backbone into a single expression plasmid, additional primer coverage of the germline repertoire (both leader sequence and framework 1), transfection of suspension HEK293 cells for higher expression, and the use of high fidelity polymerases during PCR amplification.
For the methods described here, the most critical steps are near the transition between flow cytometry and single cell cloning. First, the proper placement of sorted single cells into the plate is essential. Setting the drop-delay correctly on the sorter is a key step. Environmental factors, such as low humidity, must also be taken into account, as we have found our recovery efficiencies drop significantly unless a static gun is used on the target sort plates. Following cell placement, plates are centrifuged to ensure cells have contacted the 10 µL of buffer in bottom of the wells. All of these measures are critical for the molecular biology portion to be successful. If the conditions are sub-optimal for the reverse transcription reaction of a single cell, PCR amplification of even β-actin can be difficult. The strength of the method presented is the ability to interrogate millions of cells and only sort the ones that match the antigen reactivity criteria against the antigen of choice. This requires the signal to noise ratio to be as high as possible, which is done by optimizing bait concentrations before sorting. Dual-labeled bait is used to reduce the recovery of false-positive cells, which can occur if one of the fluorophores has high background. Using more than one antigen bait can make the signal:noise optimization more difficult, but the ability to interrogate multiple peptides simultaneously is another benefit of this method.
When recovery efficiencies are low, a set of nested β-actin primers are used to confirm that template cDNA is present. The drawback to this approach is that it is difficult to determine whether there was no cell present in the well or the reverse transcription reaction failed, making troubleshooting difficult. Occasionally the opposite will occur and the efficiencies are higher than expected. The typical recovery for heavy chain is between 30-45% and light chains are higher, between 40-60%. Each PCR reaction (Step I & II) uses 50 cycles to amplify from a single cell. The high number of total cycles also makes this method susceptible to contamination. Sequence analysis of amplicons can be used to determine whether a contaminant has been introduced, or an unusually high recovery rate has been legitimately achieved.
The utility of this method to recover native human antibodies against an antigen of choice has several significant limitations. First, only soluble proteins that can be labeled may be used as "bait" for the flow cytometry. For the sorts presented in the representative results, we used a series of synthesized overlapping peptides from tau protein, since using the whole protein proved difficult. The use of linear peptides is likely not optimal, since it may limit the identification of antibodies against non-linear or structural epitopes. However, we were able to identify several unique antibodies against tau and these are currently undergoing further evaluation 8, 9 . Another limitation is the low throughput of the molecular biology recovery and cloning of IgGs. The initial sorting strategy allows for the screening of millions of cells, but the subsequent molecular biology processing consists of multiple stages. Ongoing optimization efforts to incorporate newer technologies, such as Gibson Assembly 10 have streamlined several steps, but the bottleneck remains cloning individual heavy and light chain pairs.
The "BSelex" method utilizes the BCR expressed on the surface of memory B cells to identify cells that display antigen reactivity, and then recover these individual cells via flow cytometry 11, 12 . Due to this reliance on the BCR, the method is restricted to the memory B cell compartment, and does not capture antibody secreting cells (ASCs) such as plasmablasts. However, this approach may be advantageous to recovering a broader repertoire of antigen-specific immunoglobins when compared to ASCs. Influenza vaccination studies demonstrate that while reactive ASCs can be dominated by a small number of expanded B cell clones, the antigen-specific memory B cell population is rarely clonal 12 . The T cell receptor (TCR) on the surface of T cells possesses similarities to the B cell receptor in gene arrangement and recombination to maximize diversity. Single cell approaches similar to what is described in the method presented here have been developed for assessing the T cell repertoire, including recovery and single cell cloning of alpha and beta chains 13 . However, TCR recognition requires peptides to be presented by MHC molecules, adding significant complexity to the labeled bait approach to identify peptide-specific T cells. Unlike B cells, T cells do not undergo affinity maturation of the entire variable region, so identification of the short CDR3 region and some flanking sequence is all that is required for identification and reconstitution. Finally, this method describes the identification of IgG molecules using flow cytometry, but it is also possible to use alternative phenotypic markers to identify B cells of different isotypes.
Currently, there are methods being developed to connect the enormous amount of data collected from next generation sequencing with functional analysis of antigen specificity, but these methods are still being refined. Despite its limitations, the method described here has been used to identify antibodies with potential therapeutic value for both infectious and non-infectious diseases 8, 14, 15 , and represents a reliable approach to recover relevant antigen-specific IgGs from humans, without extensive manipulation of B cells or extensive cell culture.
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